Debt-to-equity of Prelude Therapeutics Inc from 30 Jun 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Prelude Therapeutics Inc quarterly Debt-to-equity in % history and change rate from 30 Jun 2021 to 30 Sep 2025.
  • Prelude Therapeutics Inc Debt-to-equity for the quarter ending 30 Sep 2025 was 43%, a 110% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Prelude Therapeutics Inc Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 43% +22% +110% 30 Sep 2025
Q2 2025 35% +19% +116% 30 Jun 2025
Q1 2025 29% +17% +136% 31 Mar 2025
Q4 2024 24% +13% +114% 31 Dec 2024
Q3 2024 20% +10% +104% 30 Sep 2024
Q2 2024 16% +5.3% +49% 30 Jun 2024
Q1 2024 12% +1.2% +11% 31 Mar 2024
Q4 2023 11% +1.7% +18% 31 Dec 2023
Q3 2023 10% +1.9% +24% 30 Sep 2023
Q2 2023 11% +3.8% +55% 30 Jun 2023
Q1 2023 11% +4.9% +79% 31 Mar 2023
Q4 2022 9.5% +4.3% +81% 31 Dec 2022
Q3 2022 8.1% +3.1% +64% 30 Sep 2022
Q2 2022 6.9% +2.4% +53% 30 Jun 2022
Q1 2022 6.1% 31 Mar 2022
Q4 2021 5.2% 31 Dec 2021
Q3 2021 4.9% 30 Sep 2021
Q2 2021 4.5% 30 Jun 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.